BioLineRx (BLRX) Cash from Operations (2013 - 2025)

BioLineRx's Cash from Operations history runs 13 years deep, the most recent figure standing at 3200000.0 for Q4 2025.

• In Q4 2025, Cash from Operations rose 62.83% year-over-year to 3200000.0; the TTM figure through Dec 2025 stood at 8074000.0 (up 81.6% YoY), while the FY2025 annual figure was 8074000.0, up 81.6% from the prior year.
• Cash from Operations was 3200000.0 for Q4 2025 at BioLineRx, down from 2106000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 4991000.0 in Q4 2023 to a low of 14109000.0 in Q1 2024.
• Historically, Cash from Operations has averaged 6218400.0 across 5 years, with a median of 6259000.0 in 2021.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations soared 187.82% in 2023, then tumbled 272.51% in 2024.
• A 5-year view of Cash from Operations shows it stood at 5503000.0 in 2021, then retreated by 3.27% to 5683000.0 in 2022, then jumped by 187.82% to 4991000.0 in 2023, then sank by 272.51% to 8610000.0 in 2024, then jumped by 62.83% to 3200000.0 in 2025.
• The last three Cash from Operations figures came in at 3200000.0 (Q4 2025), 2106000.0 (Q3 2025), and 177000.0 (Q2 2025), per Business Quant data.